Nilotinib Stada

Nilotinib, the active ingredient in Nilotinib Stada, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of chronic myeloid leukemia in patients with the Philadelphia chromosome-positive disease. GNH USA supplies Nilotinib Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nilotinib acts on the BCR‑ABL tyrosine kinase pathway, providing targeted therapy for chronic myeloid leukemia. - Chronic phase CML: reduces leukemic cell proliferation and achieves hematologic and cytogenetic responses. - Accelerated phase CML: helps control disease progression and improves survival outcomes. - Blast crisis CML: offers disease control when combined with other antileukemic agents.

Nilotinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools, often transient. - Rash: skin erythema or pruritus. - Headache: mild to moderate intensity. - Fatigue: generalized tiredness. - Myalgia: muscle aches or soreness.

Serious or Rare Side Effects: - QT interval prolongation: may predispose to ventricular arrhythmias. - Pancreatitis: abdominal pain with elevated enzymes. - Hepatic toxicity: elevated transaminases or bilirubin. - Severe neutropenia: marked reduction in white blood cells. - Severe thrombocytopenia: low platelet counts increasing bleeding risk. - Stevens‑Johnson syndrome: severe skin and mucosal reactions.

Nilotinib requires careful monitoring and patient education to minimize risks. - Cardiac monitoring: obtain baseline ECG and repeat periodically due to QT prolongation risk. - Liver function: assess hepatic enzymes before initiation and during therapy. - Blood counts: monitor complete blood count regularly for neutropenia or thrombocytopenia. - Drug interactions: avoid concomitant strong CYP3A4 inhibitors or QT‑prolonging agents. - Pregnancy and lactation: contraindicated; discuss contraception with patients of child‑bearing potential. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Nilotinib interacts with several drug classes that can alter its exposure or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase nilotinib plasma levels, raising toxicity risk. - QT‑prolonging agents (e.g., amiodarone, sotalol): additive effect on cardiac repolarization. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce nilotinib exposure, compromising efficacy.

Moderate Interactions (Monitor Closely): - Antacids, H2‑blockers, proton‑pump inhibitors: may decrease nilotinib absorption; separate dosing by at least 2 hours. - Warfarin: nilotinib can increase INR; monitor coagulation parameters. - Statins metabolized by CYP3A4 (e.g., simvastatin, lovastatin): risk of elevated statin levels; consider dose adjustment or alternative lipid‑lowering therapy.